Molecular Profiles, a contract research and manufacturing organization, has begun construction of a new manufacturing facility in Nottingham, U.K.

The $14.3 million investment will allow Molecular Profiles to expand its current manufacturing capabilities. The U.K. government allocated a regional growth fund grant of $2.5 million. 

The new GMP facility, planned to open in late 2012, will provide an additional 30,000 square feet of space consisting of six new GMP suites, several laboratories and a clinical packing suite. The facility will enable flexibility of use and the manufacture of highly potent compounds up to OEB 4 level. It is also designed to handle a range of dosage forms including solids, liquids, semi-solids and inhaled products. The expanded capability allows Molecular Profiles to comprehensively cover phase I and II clinical trial requirements with manufacturing batch scale of up to 30kg.

The investment will enable expansion across all Molecular Profiles’ services, including formulation development, polymorph and salt selection, analytical services, materials characterization and clinical trial manufacturing.